Rigel Pharmaceuticals

Small molecule therapeutics for autoimmune & inflammatory diseases and cancer

Rigel (NASDAQ: RIGL) is focused on discovery and development of therapeutics against novel targets implicated in autoimmune diseases, inflammatory diseases, and cancer. Rigel completed its IPO in 2000.

Status

IPO in 2000 (NASDAQ: RIGL)

Year of Investment

1997

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

South San Francisco, California

Frazier Team

Social Media